Long term potential (1-3 months)Haven't posted on here in a bit but wanted to share my thoughts and most recent investment in $RNVA.
I bought into RNVA on Tuesday at 0.083 per share for a little over 12k shares. I heard about the company through the penny stock subreddit and did some DD and decided to make an investment into it.
My thoughts are as follows- Contrary to what Stocktwits believed yesterday, this is not a stock to get rich quick from. Many people have the pipe dream of this stock becoming the next $DRYS or $ETRM. Most likely not gonna happen but I would not complain if it did.
The company is facing an impending reverse split if it cannot maintain $1+ a share by March for 10 days.
The first thing I'm watching for is for us to reach $1 a share. If we can do that within the next few months and stay above it for 10 days the reverse split will be pushed back or not necessarily entirely.
RNVA appears to have the motivation to see it reach $1 a share and to avoid an R/S, however at the end of the day it may not come near $1. In the event that it doesn't and a R/S occurs the stock soars to the company price target of $18.5 a share.
Just some thoughts
In it for the long haul
Healthcare
Health Care down big after Trump press conferenceFound support @ 55-EMA, but negative sentiment has us Bearish
Johnson&Johnson seen lower in the coming weeksThere is no real change in the dominant bear trend, as prices pressure $110.00.
Stochastics and sentiment continue to weaken, highlighting further downside risks into the coming weeks.
In tandem, Healthcare is also weakening and, along with JNJ, further underperformance relative to the SP500 Index is highlighted.
Good Short Opportunity for AetnaStrong sign showing a pullback soon.. Looks like this has been overbought..
MYGN Earnings Oversold PlayMYGN took a beating after it's guidance underwhelm last quarter.
I do believe that the reaction was overdone.
MYGN has healthy revenue streams and growing drug and generics demand.
TA confirms a re-entering into trading range of:
PT 1: $25.00 for a ~20%+ return.
PT 2: $30.00 for a 50% return.
Asterias Biotherapeutics, Inc. triangle breakout Yesterday AST closed its session gapping up and breaking an upward triangle which might become a strong bullish opportunity. Although general downward motion is still intact, double bottom which was formed at the beginning of July and triangle breakout have every chance to finish with bearish mood.
We would project the price to go up and reach at least $3.60 where it might stumble upon a gap resistance and trade down.
For more ideas visit mercurius.wordpress.com
OvaScience Inc volatility and volume are increasingWith increased volume and bullish engulfing pattern which finished double bottom formation, OVAS is an excellent pick to buy this week.
Last week global fertility company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.16. The business earned $0.19 million during the quarter, compared to analysts’ expectations of $0.21 million. The business’s revenue was up 530.0% compared to the same quarter last year.
For more ideas visit: mercuriusam.wordpress.com
Short $HTBX Irrational HypeOh., how great... management bought some stock at $0.75 and they took back a public offering. The stock climbed and has momentum, but why? The company is still producing revenues of $0 and ops are getting more expensive. Earnings keep getting more negative, don't expect anything good to come out of their reporting coming up in August. Short at ~1.15 this morning and exit back at the 50-day moving average of $0.70-0.-75 in a few days. NASDAQ:HTBX
Ligand Pharmaceuticals best choise in the Biopharma IndustryFundamentals :
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines worldwide. Ligand Pharmaceuticals has a compelling business model that offers higher than average return with lower than average risk.
Ligand's P/E of 8 is cheap as I mentioned. Forward P/E is indeed higher compared to the industry but I think it is still in range. Even if it is expensive, I think it is justified given the high return to equity that Ligand has generated in 2015. And as a growth stock, Ligand's growth comes at a cheaper price compared to the industry as represented by PE/G. So, do I think Ligand's a buy at this level? I think so
Technicals :
Price broke important level of resistance at $112 and had a nice run to $132. No we are in pullback, restesting previous resistance that now can act like support. And looks like we are curling up and can see new highs soon
Trade and Risk management:
We already have an initial entry, as price came out of consolidation above $121.40. I will initiate small position here with stop below $114.50 and will see if it can build new construction in front of high at $131.85 ot add to my position.
Amedisys has more room to runFundamentals :
Amedisys provides home health, and hospice and personal care services. The market Amedisys serves is expected to grow in the future. The company's earnings growth has averaged 46.3% over the past three years, while the industry has seen its bottom line increase at a far lesser rate of 3.2%. With the macro environment proving favorable for Amedisys, this trend is expected to sustain ahead.
Technicals :
Price is near all time highs, building a nice and narrow pattern. Price is above all key moving averages.
Trade and Risk management:
Break out of triangle will trigger an Entry Long around $54.30. Stop will be below $48.50 and respective target at $65
Medtronic rising to the sky Fundamentals :
It's not every day that you find a solid company operating in a growing industry which also happens to be a dividend aristocrat. Medtronic is such a company. Company is operating in the healthcare industry, being the largest medical technology company in the world. Today before market open company releases tis earnings report.
Technical :
Price broke up and holds above important resistance level $79. Price above all key moving averages.
Trade and Risk management :
Break above $82 will trigger Entry Long with stop below $80.60 and target around $88
Healthcare,biotech, pharmaceuticals stocks looking AttractiveMoney flow is at the lowest point of 2016 attract
Canopy Growth Corp. Stock PricesThis shows the stock prices of Canada's largest medical marijuana company.
Canopy Growth Corp. Stock Prices This tracks Canada's largest medical marijuana company's stock prices.
XLV ShortYou can thank that little price hiking hedge fund manager and people like Bill Ackman for the Healthcare/Pharmaceutical correction. Looking at the weekly using Fibs as reference points i believe healthcare over the next few months will begin to sell. I have a target of the 1.618 extension of 59.76 and a second target of 53.31. I'm using XLV to short because everything else is too expensive... you can play this through ITM puts or buy a longterm out of the money put at a 62 or 60 strike for next year.
Feel free to leave comments or questions.
-Ryanhasoptions.
Johnson & Johnson vs USDJohnson & Johnson has seen extreme price consolidation since last November. Since they are a highly diversified healthcare company, currency translations affect their bottom line quite substantially. With the recent contraction of the US Dollar, Johnson & Johnson has broken out of a prolonged trading range. If the dollar continues to contract against other foreign currencies, Johnson & Johnson will make better on their hedges and increase the bottom line substantially, thus increasing free cash flow and overall economic opportunity.
On Break LongXLV could move nicely as the healthcare stocks continue to advance, watch for a breakout with volume to take the trade and stop 8% down
